Cargando…
Carcinoid Heart Disease: How to Diagnose and Treat in 2020?
Neuroendocrine tumors (NETs, originally termed “carcinoids”) create a relatively rare group of neoplasms with an approximate incidence rate of 2.5 to 5 cases per 100 000 persons. Roughly 30% to 40% of subjects with NETs develop carcinoid syndrome (CS), and 20% to 50% of subjects with CS are diagnose...
Autores principales: | Bober, Barbara, Saracyn, Marek, Kołodziej, Maciej, Kowalski, Łukasz, Deptuła-Krawczyk, Elżbieta, Kapusta, Waldemar, Kamiński, Grzegorz, Mozenska, Olga, Bil, Jacek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597558/ https://www.ncbi.nlm.nih.gov/pubmed/33192110 http://dx.doi.org/10.1177/1179546820968101 |
Ejemplares similares
-
Renal Disturbances during and after Radioligand Therapy of Neuroendocrine Tumors—Extended Analysis of Potential Acute and Chronic Complications
por: Saracyn, Marek, et al.
Publicado: (2023) -
Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms
por: Saracyn, Marek, et al.
Publicado: (2022) -
SUN-274 Pituitary Macroadenoma Treated with Peptide Receptor Radionuclide Therapy in a Patient with Common Variable Immunodeficiency - Case Report
por: Brodowska-Kania, Dorota, et al.
Publicado: (2020) -
The vicious cycle: a history of obesity and COVID-19
por: Bil, Jacek, et al.
Publicado: (2021) -
Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [(177)Lu]Lu-DOTA-TATE or [(177)Lu]Lu-DOTA-TATE and [(90)Y]Y-DOTA-TATE—A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
por: Durma, Adam Daniel, et al.
Publicado: (2023)